News & Press Releases


August 11, 2022
Meet us at CPHI 2022:
Meet the team of Grünenthal PRO November 1-3, 2022 at the CPhI Worldwide in Frankfurt, Germany - Booth 120F12 and learn about our contract manufacturing business. Our five production sites across Europe and Latin America offer a broad portfolio including biopharma services and support a diverse global customer base. We offer a selected range of products which includes Tramadol HCl or Betahistine diHCl, as API, bulk and/ or finished dosage form. We look forward to connecting with you and providing added value for even more partners in the future. Read more

May 25, 2022
Impressions from our Italian production site Our manufacturing site in Origgio stands for efficiency, innovation and quality. This allows for an uninterrupted supply of medicine to patients. The site produces over 2 billion tablets per year and was recently expanded to produce a nasal spray against migraines. View Video

March 31, 2022
Sucessfull inspection of Grünenthal's manufacturing facility in Germany
Grünenthal's manufacturing facility in Germany recently passed an inspection by the U.S. Food and Drug Administration (FDA) with an excellent outcome: No objectionable conditions or practices were found. The modern multi-purpose plant currently supplies more than 100 countries with six different Active Pharmaceutical Ingredients (APIs). It also serves as a full-service CMO with a service portfolio including controlled drugs handling, regulatory services, production process design and export.

March 22, 2022
Meet us at BePharma virtual 2022
Meet the team of Grünenthal PRO at the BePharma virtual 2022 and learn about our contract manufacturing business. Our five production sites across Europe and Latin America offer a broad portfolio including biopharma services and support a diverse global customer base. We look forward to connecting with you and providing added value for even more partners in the future.

December 21, 2021
Recap 2021
2021 was a challenging year for manufacturing and supply. In our five specialised production plants, our colleagues have successfully supported pharmaceutical partners worldwide. They managed an uninterrupted production and maintained the supply of medicines to patients. Listen to Birgit Jansen, Head of Contract Manufacturing Business at Grünenthal. Read more

November 18, 2021
LED bulbs as a shining example
Small changes can make a big difference. By swapping thousands of traditional lightbulbs for LED bulbs at our sites, Grünenthal is saving energy and reducing emissions – and further reducing its environmental footprint. Read more

August 31, 2021
Grünenthal’s site in Mitlödi is powered by green energy
Grünenthal’s team at its API site in Mitlödi is taking action to protect the environment and has now switched to 100 per cent renewable energy from a nearby source. Find out more about this achievement and our team’s big plans for a greener future. Read more

August 12, 2021
Grünenthal’s manufacturing sites now send zero waste to landfill
Grünenthal’s manufacturing sites worldwide have hit a key target: they now send zero waste to landfill. This achievement marks a big step forward in our strong commitment to cutting our environmental footprint and promoting sustainability. Read more

June 24, 2021
Winning awards for our commitment to quality
During a solemnly virtual event in May, Grünenthal received the “Masters of Excellence Quality Champion” award from its supplier, MasterControl. This prestigious prize recognises our dedicated efforts to boost quality and digitalisation worldwide. Read more

January 21, 2021
Grünenthal Colombia achieves top ranking for outstanding logistics
Our affiliate in Colombia recently achieved second place in a national ranking of logistics processes for companies in the health sector. This strong result shows that our new collaborative approach is creating real value for customers and patients. Read more

October 01, 2020
Responding to the biggest ever change in the pharmaceutical industry
The Falsified Medicines Directive aims to prevent the distribution of counterfeit medicines in the EU. We successfully adapted our processes in line with this directive last year – and we are now implementing further measures in non-EU countries. Read more

June 10, 2020
Novartis presents “Partner of the Year” award to Grünenthal’s manufacturing site in Ecuador:
The global healthcare company Novartis has presented its award for “Partner of the Year 2019” to Grünenthal’s site in Quito, Ecuador. The award recognises outstanding quality, efficiency and commitment – and is the company’s most prestigious prize for the best supplier in all categories in the whole Andean Region. Read more

April 16, 2020
Grünenthal hormone production site in Santiago de Chile awarded key Brazilian government certification:
Grünenthal’s production site in Santiago de Chile is now certified by ANVISA, the Brazilian Health Regulatory Authority. This success further strengthens Grünenthal’s Contract Manufacturing Business and opens up opportunities to supply hormones and women’s health products in Brazil. Read more

February 15, 2020
Successful FDA inspection for Grünenthal’s manufacturing site in Italy:
Our Italian site near Milan has become the second site in Grünenthal’s global manufacturing network to be successfully inspected by the FDA – following our production location in Switzerland. The site passed the inspection with zero findings. This excellent outcome confirms the outstanding quality level maturity and overall quality performance of the Grünenthal manufacturing network. The inspection focused on the biopharma assembly and packaging section of our Italian site. This success will provide the basis for expansion of Grünenthal’s contract manufacturing business.

October 02, 2019
Delighting contract manufacturing customers with a high-tech site in Italy:
The team at Grünenthal’s production site in Italy recently hit two important milestones – gaining official approval for the refurbishment of the 2,000-square-metre production hall, as well as for new facilities for its biopharma services. Read more

February 09, 2019
New Medicines Verification System - We protect our patients against falsified pharmaceutical products:
As Grünenthal, we are 100 percent committed to supporting the FMD and its aim of increasing safety for patients – and we now have everything in place to bring this legislation to life. We joined forces with partners from across industries through our participation in a working group within the European Federation of Pharmaceutical Industries & Associations (EFPIA), as well as through involvement in the European Medicines Verification Organisation (EMVO) User Group. Read more

July 23, 2018
Grünenthal is setting a new standard in global demand and supply planning capabilities.
We have just implemented a new IT solution, SAP Integrated Business Planning, to support the end-to-end IBP process and provide precise and adaptive planning possibilities, automation and seamless data integration. Another major step forward to strengthen our delivery reliability for our Contract Manufacturing Business customers.

June 29, 2018
Today our colleagues in Switzerland celebrate a major milestone:
For 25 years they are producing Tramadol in Mitlödi for the global market – this is the world’s largest production unit for Tramadol Hydrochloride. We operate an API-production in top quality: well trained workforce, state of the art facility, precisely controlled processes and efficient Equipment.  

May 23, 2018
TECNANDINA, our Manufacturing Site in Ecuador, was honored from Novartis Ecuador with the annual award “Best Logistic Service Supplier in the Andean Cluster”.
Read more:

February 2018
Interview in World Pharmaceutical Frontiers

January 12, 2017
Grünenthal introduces Latin America’s most modern women’s health products plant Santiago de Chile:
Grünenthal, an R&D-driven, privately owned international pharmaceutical company with headquarters in Germany, announced the introduction of its new women’s health products plant today. Grünenthal invested USD 14.5 million to build the 1,150 m2 hormone plant, which is the company’s center of excellence for hormone production and the most modern in Latin America. Read more

December 14, 2016
Grünenthal’s manufacturing site in Ecuador, Tecnandina, receives European GMP certification for the third time:
The Grünenthal Group announces today that its manufacturing site in Ecuador, Tecnandina, successfully passed the inspection to manufacture in accordance with the European GMP regulations. The certification covers the production of solid and semi-solid pharmaceuticals for the third time and now, for the first time, also liquid pharmaceuticals. This GMP Certificate will be valid for another three years. Read more

October 1, 2015
Grünenthal receives Brazilian ANVISA certification for Tecnandina production plant in Ecuador:
The Grünenthal Group announces that its Tecnandina manufacturing plant in Ecuador has received certification from the Regulatory Authority of Brazil, ANVISA (Agência Nacional de Vigilância Sanitária, Brazilian Health Surveillance Agency). This will allow Tecnandina to export pharmaceutical products also to Brazil and makes it the first production plant in Ecuador to receive ANVISA certification. Read more